News

Category Archives: International Pharmaceutical Regulatory Monitor

NICE Recommends Kadcyla, Kyprolis and Rejects Besponsa Coverage

By | International Pharmaceutical Regulatory Monitor | No Comments

The U.K. is planning to move Roche’s Kadcyla (trastuzumab emtansine) into the NHS’s routine funding programs later this summer, following guidance from the National Institute for Health and Care Excellence and an agreement from Roche to lower the cost of the breast cancer treatment.
Source: International Pharmaceutical Regulatory Monitor

EC Publishes New Action Plan for Antimicrobial Resistance

By | International Pharmaceutical Regulatory Monitor | No Comments

The European Commission updated its 2011 action plan against antimicrobial resistance, pledging to boost research into the development of new treatments and alternatives — including support for small- and medium-sized companies — and develop guidelines for the prudent use of the drugs.
Source: International Pharmaceutical Regulatory Monitor